Mission:

We aim to uncover the etiology, understand the pathogenesis, and develop novel therapeutics for multiple hematologic malignancies with a focus on large granular lymphocyte (LGL) leukemia, peripheral T cell lymphoma (PTCL), and acute myeloid leukemia (AML).

We employ numerous research techniques including molecular biology, biochemistry, systems biology, cell biology, cell signaling, and bioinformatics to interrogate human cell lines and primary patient samples.

We seek to push the boundaries of our research within a welcoming, fun, and energetic lab environment with mutual respect and inclusivity.

Research:

1. Defining the somatic molecular alterations, genomic landscape, and functional consequences of recurrent molecular alterations in LGL leukemia pathogenesis

2. Identifying and characterizing the role of endogenous retroviruses in LGL leukemia pathogenesis

3. Investigating targets and mechanisms of action for experimental and approved therapeutics for LGL leukemia and PTCL

4. Exploring the overlapping pathogenic mechanisms and therapeutic vulnerabilities between LGL leukemia and PTCL

5. Developing novel sphingolipid-based therapeutics for AML

6. Leveraging novel nanoformulations of experimental/approved anti-cancer compounds to improve pharmacokinetics, bioavailability, and therapeutic efficacy in collaboration with Dr. Anuradha Illendula.

Prospective Students:

We are actively recruiting new graduate students and MD/PhD candidates. Check out the Prospective Students tab to learn more!